Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib with Autologous Stem Cell Transplant for Myelofibrosis
NCT02469974Withdrawn
- Start
- May 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of ruxolitinib in myelofibrosis (MF). Primary endpoint: Safety of combining ruxolitinib with autologous HSCT measured by graft failure or death at 2 years. Planned start May 2015; status: withdrawn.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02469974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02469974.